Activating Cl- secretion

Abstract

Compounds represented by formula (I), wherein A is a 5 or 6-membered unsaturated heterocyclic ring containing at least one N atom; B is X 2 is O, NH, NR, CH 2 , CHR or CR 2 , each R individually is alkyl, cycloalkyl, aryl, alkaryl and aralkyl, each R 2 individually is H, alkyl, cycloalkyl, aryl, alkaryl, and aralkyl; Y is a halogen; alkythio group or nitrogenous moiety, are useful for activating Cl − secretion, and can be used for treating cystic fibrosis.

What is claimed is:  
     
         1 . A method for promoting Cl −  secretion in a patient in need thereof which comprises administering to said patient a composition comprising a pharmaceutically acceptable carrier and an amount effective for promoting or activating Cl— secretion of a compound represented by the formula:  
       
         
           
           
               
               
           
         
       
       wherein A is a 5 or 6 membered unsaturated heterocyclic ring containing at least one N atom;  
       
         
           
           
               
               
           
         
         X2 is O, NH, NR, CH 2 , CHR or CR 2    
         each R individually is alkyl, cycloalkyl, aryl, alkaryl and aralkyl,  
         each R2 individually is H, alkyl, cycloalkyl, aryl, alkaryl and aralkyl;  
         Y is a halogen; alkythio group or nitrogenous moiety.  
       
     
     
         2 . The method of  claim 1  wherein the alkyl moieties of said R and R 2  groups contain 1-22 carbon atoms and the aryl moieties of said R groups contain 6-14 carbon atoms.  
     
     
         3 . The method of  claim 1  wherein each R individually is selected from the group consisting of methyl, ethyl, isopropyl, n-butyl, hexyl, hexenyl, octyl, decyl, dodecyl, phenyl, benzyl and phenethyl.  
     
     
         4 . The method of  claim 1  wherein said compound is 5-diazoimidazole-4-carboxylic acid n-octyl ester.  
     
     
         5 . The method of  claim 1  wherein said compound is selected from the group of compounds represented by the formulae:  
       
         
           
           
               
               
           
         
       
     
     
         6 . A method for treating a patient suffering from cystic fibrosis which comprises administering to said patient a composition comprising a pharmaceutically acceptable carrier and an amount effective for promoting or activating Cl— secretion of a compound represented by the formula:  
       
         
           
           
               
               
           
         
       
       wherein A is a 5 or 6 membered unsaturated heterocyclic ring containing at least one N atom;  
       
         
           
           
               
               
           
         
         X2 is O, NH, NR, CH 2 , CHR or CR 2    
         each R individually is alkyl, cycloalkyl, aryl, alkaryl and aralkyl,  
         each R2 individually is H, alkyl, cycloalkyl, aryl, alkaryl and aralkyl;  
         Y is a halogen; alkythio group or nitrogenous moiety.  
       
     
     
         7 . The method of  claim 6  wherein the alkyl moieties of said R and R 2  groups contain 1-22 carbon atoms and the aryl moieties of said R groups contain 6-14 carbon atoms.  
     
     
         8 . The method of  claim 6  wherein each R individually is selected from the group consisting of methyl, ethyl, isopropyl, n-butyl, hexyl, hexenyl, octyl, decyl, dodecyl, phenyl, benzyl and phenethyl.  
     
     
         9 . The method of  claim 6  wherein said compound is 5-diazoimidazole-4-carboxylic acid n-octyl ester.  
     
     
         10 . The method of  claim 6  wherein said compound is selected from the group of compounds represented by the formulae: